CT-868 Dual Agonist Targets Blood Sugar and Obesity in Phase 2 Diabetes Trial
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Summary
CT-868 is an experimental drug developed by Carmot Therapeutics being evaluated for its ability to control blood sugar in adults with Type 2 diabetes. This completed Phase 2 clinical trial enrolled overweight and obese adults whose Type 2 diabetes was not adequately controlled, comparing CT-868 against placebo. The primary goal was to measure reductions in HbA1c, a key marker of long-term blood sugar control. While the abstract does not describe CT-868's mechanism, the drug has been publicly characterized elsewhere as a dual GLP-1/GIP receptor agonist — a class that includes tirzepatide and has shown strong effects on glucose and weight. Completion of this Phase 2 trial marks a milestone in understanding CT-868's safety and efficacy, though detailed results are not contained in the trial registry record.
Detailed Summary
Type 2 diabetes and obesity are tightly linked metabolic disorders affecting hundreds of millions worldwide, and inadequate blood sugar control remains a leading driver of cardiovascular disease, kidney failure, and premature death. Finding therapies that address both conditions simultaneously has become a major priority in metabolic medicine.
CT-868, developed by Carmot Therapeutics, is an investigational therapy being evaluated in overweight and obese adults with inadequately controlled Type 2 diabetes. This Phase 2 trial compared CT-868 against placebo, with the primary objective of lowering HbA1c — the gold-standard measure of sustained glycemic control. The trial registry abstract does not describe CT-868's molecular mechanism; however, publicly available information outside this record characterizes CT-868 as a dual GLP-1/GIP receptor agonist.
The trial is listed as completed, though full efficacy and safety results are not disclosed in the available registry entry. The study design — placebo-controlled and focused on HbA1c as a primary endpoint — follows established regulatory standards for diabetes drug development.
For context, dual GLP-1/GIP agonism has been clinically validated by tirzepatide (Mounjaro/Zepbound), which demonstrated superior HbA1c and weight reduction versus GLP-1 mono-agonists. Externally reported corporate activity — including Roche's acquisition of Carmot Therapeutics announced in late 2023 — is not part of this registry record but provides relevant context for the asset's trajectory.
Caveats include the limited information available from the registry abstract alone, the absence of disclosed results, and the Phase 2 scale, which means larger confirmatory trials would be required before clinical adoption.
Key Findings
- CT-868 was evaluated in a completed Phase 2 trial in overweight and obese adults with inadequately controlled Type 2 diabetes.
- The trial compared CT-868 against placebo, with HbA1c reduction as the primary endpoint.
- The sponsor was Carmot Therapeutics; the registry entry does not disclose efficacy or safety results.
- The registry abstract does not specify CT-868's mechanism of action; external sources describe it as a dual GLP-1/GIP receptor agonist.
- HbA1c reduction is the standard regulatory benchmark for long-term diabetes drug development.
Methodology
Phase 2 trial sponsored by Carmot Therapeutics in overweight or obese adults with inadequately controlled Type 2 diabetes. Listed interventions are CT-868 and placebo; the registry abstract does not explicitly state randomization or blinding methodology. The primary outcome was change in HbA1c.
Study Limitations
This summary is based only on a ClinicalTrials.gov registry abstract, which does not report effect size, safety outcomes, statistical analyses, or mechanism of action. Randomization and blinding are not explicitly described. Phase 2 trials are not powered for definitive efficacy conclusions, and Phase 3 confirmation would be required before clinical use.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.